Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial)

Jürgen Krauter*, Walter Fiedler, Richard F. Schlenk, Peter Paschka, Felicitas Thol, Michael Lübbert, Mohammed Wattad, Mareike Verbeek, Christian Könecke, Barbara Neuhaus, Armin Papkalla, Maxim Kebenko, Melanie Janning, Konstanze Döhner, Verena I. Gaidzik, Heiko Becker, Christine Greil, Peter Reimer, Katharina S. Götze, Hartmut DöhnerArnold Ganser, Michael Heuser

*Korrespondierende/r Autor/-in für diese Arbeit
2 Zitate (Scopus)

Abstract

This open-label, multicentre phase I/II study determined the maximum tolerated dose (MTD), safety and efficacy of clofarabine administered with cytarabine and idarubicin in newly diagnosed acute myeloid leukaemia (AML) patients lacking favourable genetic aberrations. The MTD was 30 mg/m2 clofarabine for patients below and above 60 years. The most frequently reported grade 3–4 non-haematological adverse events were infectious and gastrointestinal toxicities. Complete remission (CR)/CR with incomplete recovery rate was 67%. Allogeneic haematopoietic cell transplantation in first remission was feasible in a high proportion of younger AML patients and probably contributed to the favourable outcome compared to historical controls.

OriginalspracheEnglisch
ZeitschriftBritish Journal of Haematology
Jahrgang183
Ausgabenummer2
Seiten (von - bis)235-241
Seitenumfang7
ISSN0007-1048
DOIs
PublikationsstatusVeröffentlicht - 10.2018

Fingerprint

Untersuchen Sie die Forschungsthemen von „Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial)“. Zusammen bilden sie einen einzigartigen Fingerprint.

Zitieren